Previous 10 | Next 10 |
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the closing of its previo...
Titan Medical (NASDAQ: TMDI ) -52% on filing amended prospectus and withdrawing previous milestones. More news on: Titan Medical Inc., Westwater Resources, Inc., TDH Holdings, Inc., Stocks on the move, Read more ...
Gainers: ABC +7.0% . CAH +8.1% . MCK +7.5% . SNBR +4.8%. ENDP +4.6% . More news on: AmerisourceBergen Corporation, Cardinal Health, Inc., McKesson Corporation, Stocks on the move, , News on ETFs Read more ...
The FDA grants Rare Pediatric Disease designation for ProQR Therapeutics' (NASDAQ: PRQR ) sepofarsen for the treatment of Leber congenital amaurosis type 10 (LCA10). More news on: ProQR Therapeutics N.V., Healthcare stocks news, Stocks on the move, Read more ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pediat...
The following slide deck was published by ProQR Therapeutics N.V. in conjunction with this Read more ...
ProQR Therapeutics (NASDAQ: PRQR ) announces positive topline results from a Phase 1/2 clinical trial evaluating sepofarsen (QR-110) in patients with Leber congenital amaurosis type 10 (LCA10) due to a certain mutation in the CEP290 gene. More news on: ProQR Therapeutics N.V., Healthca...
Reported rapid, significant and durable improvements in vision at twelve months Concordant improvement in key secondary outcome measures The target registration dose of sepofarsen was well-tolerated with a favorable benefit/risk profile Strengthens confidence in the ongoing Phase 2/3 p...
Gainers: Five Prime Therapeutics (NASDAQ: FPRX ) +19% . Ocugen (NASDAQ: OCGN ) +19% . Navios Maritime Holdings (NYSE: NM ) +16% . RISE Education Cayman (NASDAQ: REDU ) +15% . The National Security Group (NASDAQ: NSEC ) +15% . Catabasis Pharmaceuticals (NASDAQ: CATB ) +15% . ele...
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that mana...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massa...
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...